uniQure (NASDAQ:QURE) Trading 7.9% Higher – Should You Buy?

Shares of uniQure N.V. (NASDAQ:QURE) rose 7.9% during mid-day trading on Wednesday . The stock traded as high as $42.00 and last traded at $39.5390. 654,926 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 2,558,914 shares. The stock had previously closed at $36.66.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: AMT-130 regulatory milestones remain on track. uniQure expects to submit U.S. and U.K. regulatory applications in the third quarter of 2026, with four-year Phase I/II data anticipated in September. A potential regulatory review, including an expected advisory committee meeting, keeps the company’s lead program in focus. uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
• Positive Sentiment: Strong cash position reduces near-term financing risk. Following a $259 million follow-on offering, uniQure reported $810.3 million in cash, cash equivalents and current investments at June 30. Management expects funding to cover operating expenses into 2030, including a potential AMT-130 launch and pipeline investment. uniQure outlines AMT-130 BLA this quarter
• Positive Sentiment: Analyst optimism increased. Wells Fargo raised its price target from $60 to $75 and maintained an “overweight” rating, signaling confidence in AMT-130’s regulatory and commercial potential. Wells Fargo price-target update
• Positive Sentiment: Early AMT-260 data showed substantial seizure reductions in three of six low-dose patients, alongside a favorable initial safety profile, providing an additional pipeline catalyst.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a report on Wednesday, June 17th. Wolfe Research upgraded uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective for the company in a research note on Wednesday. Barclays decreased their target price on uniQure from $65.00 to $60.00 and set an “overweight” rating for the company in a research report on Thursday. Mizuho lifted their target price on uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of uniQure in a report on Friday, June 26th. Thirteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $65.00.

uniQure Trading Up 5.3%

The company has a quick ratio of 10.40, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. The firm has a 50 day moving average of $37.10 and a 200 day moving average of $26.13. The firm has a market cap of $2.66 billion, a PE ratio of -10.52 and a beta of 0.90.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The firm had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same period last year, the company posted ($0.69) earnings per share. Equities analysts anticipate that uniQure N.V. will post -3.39 earnings per share for the current year.

Insider Activity at uniQure

In related news, insider Walid Abi-Saab sold 45,000 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $25.06, for a total value of $1,127,700.00. Following the sale, the insider directly owned 169,669 shares in the company, valued at approximately $4,251,905.14. The trade was a 20.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total transaction of $526,526.10. Following the sale, the director directly owned 43,254 shares in the company, valued at approximately $1,949,025.24. This trade represents a 21.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 433,229 shares of company stock worth $17,944,799 in the last three months. Corporate insiders own 4.65% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several large investors have recently modified their holdings of QURE. Avoro Capital Advisors LLC lifted its stake in shares of uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after buying an additional 1,705,556 shares in the last quarter. Aberdeen Group plc boosted its holdings in uniQure by 25.1% in the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after buying an additional 738,897 shares during the period. State Street Corp grew its stake in uniQure by 123.8% in the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after buying an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. grew its stake in uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after buying an additional 1,785,275 shares in the last quarter. Finally, Orbimed Advisors LLC raised its holdings in uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after acquiring an additional 1,398,749 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.